论文部分内容阅读
目的:探讨阿司匹林肠溶片联合阿托伐他汀预防脑梗死再发的临床疗效。方法:120例急性脑梗死患者随机分为对照组与观察组各60例,两组均给予急性脑梗死常规治疗,对照组同时予阿司匹林肠溶片150 mg,po,qn;观察组同时予阿司匹林肠溶片150 mg,po,qn,阿托伐他汀片10～20 mg,po,qn。比较两组患者治疗1年后病死率、脑缺血事件发生率及血脂、高敏C反应蛋白(hs-CRP)的改变。结果:治疗后1年,两组患者病死率分别为3.3%和5.0%(P>0.05);但观察组脑缺血事件发生率显著低于对照组(15.0%vs 36.7%,P<0.05);观察组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)及hs-CRP水平显著低于对照组(P<0.01)。结论:阿司匹林联合阿托伐他汀治疗脑梗死,可显著降低血脂及hs-CRP水平,减少脑缺血事件发生率,在脑血管病二级预防中应给予多方面的综合治疗。
Objective: To investigate the clinical efficacy of aspirin enteric-coated tablets combined with atorvastatin in the prevention of recurrent cerebral infarction. Methods: 120 patients with acute cerebral infarction were randomly divided into control group and observation group of 60 cases, both groups were given routine treatment of acute cerebral infarction, while the control group to aspirin enteric-coated tablets 150 mg, po, qn; observation group also aspirin Enteric-coated tablets 150 mg, po, qn, atorvastatin tablets 10 ~ 20 mg, po, qn. The mortality, the incidence of cerebral ischemia and the changes of serum lipids and high-sensitivity C-reactive protein (hs-CRP) were compared between the two groups after one year of treatment. Results: At 1 year after treatment, the case fatality rates in the two groups were 3.3% and 5.0%, respectively (P> 0.05). However, the incidence of cerebral ischemia in the observation group was significantly lower than that in the control group (15.0% vs 36.7%, P <0.05) (TG), total cholesterol (TC), low density lipoprotein (LDL) and hs-CRP in the observation group were significantly lower than those in the control group (P <0.01). Conclusion: Aspirin combined with atorvastatin can significantly reduce blood lipid and hs-CRP levels and reduce the incidence of cerebral ischemic events, and should be given comprehensive treatment in secondary prevention of cerebrovascular disease.